About: Evaluating the adequacy of Prima Covid-19 IgG/IgM Rapid Test for the assessment of exposure to SARS-CoV-2 virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluating the adequacy of Prima Covid-19 IgG/IgM Rapid Test for the assessment of exposure to SARS-CoV-2 virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluating the adequacy of Prima Covid-19 IgG/IgM Rapid Test for the assessment of exposure to SARS-CoV-2 virus
Creator	Carrisi, Chiara Foresti, Luca Lorenzo, Giulia Lurani, Caterina Toniolo, Paolo
Source	MedRxiv
abstract	The outbreak of the SARS-CoV-2 in early 2020 found health authorities worldwide unprepared to control the pandemic. The adoption of accurate, rapid and inexpensive methods to identify infected subjects in the general population is of paramount relevance for the control of the disease. We evaluated one of the available serological tests, the Prima Lab Covid-19 IgG/IgM Rapid Tests, on 739 volunteers. We first assessed the test's reproducibility by administering it twice on the same day on 104 subjects obtaining and overall score of 93 percent. Since the intensity of the color in the test line regions varies depending on the concentration of Covid-19 antibodies in each sample and that the determination of the positivity depends strictly on the subjective assessment by the reader, after excluding the subjects whose color intensity was too tenuous to be deemed unquestionably positive by the reader the reproducibility increased to 96%. The test would not perform properly for 6 subjects for a very limited overall technical failure of 0.83%. For 138 subjects information was available regarding a previous Real Time PCR nasopharyngeal swab test performed elsewhere. The correspondence of positive results between the two tests was 90.58% (125/138). In spite of some limitation owing especially to the choice of a self selected population sample, we conclude that Prima Lab Covid-19 IgG/IgM Rapid Test represents a low-cost, easily applicable and reproducible tool in detecting SARS-Cov-2 diffusion in the general population.
has issue date	2020-06-03(xsd:dateTime)
bibo:doi	10.1101/2020.05.30.20117424
has license	medrxiv
sha1sum (hex)	efded16e6cf1e57b78c37aff94ba3fc68f96ad25
schema:url	https://doi.org/10.1101/2020.05.30.20117424
resource representing a document's title	Evaluating the adequacy of Prima Covid-19 IgG/IgM Rapid Test for the assessment of exposure to SARS-CoV-2 virus
resource representing a document's body	covid:efded16e6cf1e57b78c37aff94ba3fc68f96ad25#body_text
is schema:about of	named entity 'early' named entity 'positivity' named entity 'Rapid' named entity 'antibodies' named entity 'Test' named entity 'TEST' named entity 'PERFORM' named entity 'SEROLOGICAL TESTS' named entity 'PRIMA' named entity 'TESTS' named entity 'DISEASE' named entity 'ONE OF' named entity 'COLOR' named entity 'LINE' named entity 'PERCENT' named entity 'LAB' named entity 'CORRESPONDENCE' named entity 'TWICE' named entity 'VERY LIMITED' named entity 'EVALUATED' named entity 'TOO' named entity 'SELF' named entity 'TO CONTROL' named entity 'IGG' named entity 'DAY' named entity 'subjects' named entity 'Lab' named entity 'score' named entity 'reproducibility' named entity 'positive' named entity 'The' named entity 'Covid-19' named entity 'test' named entity 'Test' named entity 'subjects' named entity 'subjects' named entity 'IgG' named entity 'control' named entity 'properly' named entity 'choice' named entity 'IgM' named entity 'Covid-19' named entity 'SARS-Cov-2' named entity 'antibodies' named entity 'Rapid Test' named entity 'Rapid' named entity 'rapid tests' named entity 'RT-PCR' named entity 'asymptomatic carriers' named entity 'double check' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'IgG/IgM' named entity 'infection' named entity 'IgM' named entity 'Rapid tests' named entity 'Covid-19' named entity 'Rapid test' named entity 'control line' named entity 'SARS-CoV-2' named entity 'Rapid Test' named entity 'IgG/IgM' named entity 'IgG/IgM' named entity 'IgG' named entity 'IgG/IgM' named entity 'median age' named entity 'Rapid Test' named entity 'IgG/IgM' named entity 'diagnostic tests' named entity 'Rapid Tests' named entity '10/90' named entity 'IgM' named entity 'RT-PCR' named entity 'IgG/IgM' named entity 'Covid-19' named entity 'feces' named entity 'general population' named entity 'Italian' named entity 'epidemiological' named entity '85%' named entity 'PCR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software